Chuck Silberstein, M.D., M.B.A.
NovaBridge Biosciences, Inc. (NASDAQ: NBP), a Rockville, Maryland-based biotechnology company, has appointed Chuck Silberstein, M.D., M.B.A., as Chief Financial Officer, effective November 2, 2026, as the company advances its clinical development programs and evaluates strategic financing and partnership opportunities.
Silberstein succeeds Kyler Lei, who is stepping down following his tenure with the company.
The appointment brings more than 25 years of experience in biotechnology leadership, corporate finance, capital markets, business development and healthcare investing to NovaBridge’s executive team.
As Chief Financial Officer, Silberstein will support the company’s financial strategy, capital allocation, investor relations and evaluation of strategic transactions as NovaBridge advances its portfolio of therapeutic development programs.
His appointment comes as the company focuses on progressing its lead clinical assets while pursuing financing and partnership structures suited to individual development opportunities.
“Chuck’s combination of biotechnology operating experience, public-company financial leadership and capital markets expertise is particularly relevant as we enter an important phase of execution across the NovaBridge portfolio,” said Srishti Gupta, M.D., M.P.P., Chief Executive Officer of NovaBridge.
Gupta said Silberstein’s experience leading financing transactions, engaging institutional investors and evaluating business development opportunities will support the company’s efforts to manage capital and pursue strategic transactions.
Most recently, Silberstein served as Co-Founder and Chief Executive Officer of FytonBio, gaining experience leading a biotechnology business and overseeing its corporate development activities.
Previously, he served as Chief Financial Officer of GentiBio, a biotechnology company, where his responsibilities included financial leadership and supporting corporate strategy.
He also held the positions of Chief Financial Officer and Head of Business Development at Applied Therapeutics, a formerly Nasdaq-listed biotechnology company.
At Applied Therapeutics, Silberstein oversaw corporate finance, capital markets, investor relations, business development and strategic planning.
His work included managing public financing transactions and maintaining relationships with institutional investors, research analysts and other capital markets participants.
Earlier in his career, Silberstein held leadership responsibilities in business development and research and development strategy at Allergan.
He also worked as a healthcare investor and analyst with J.P. Morgan Asset Management, BNY Mellon and Goldman Sachs Asset Management.
His experience across biotechnology operations and institutional investing provides familiarity with both the financing requirements of drug development companies and the investment considerations of healthcare-focused capital providers.
Silberstein earned a Master of Business Administration in Finance from Columbia Business School and a Doctor of Medicine degree with Distinction in Research from Albert Einstein College of Medicine.
He also holds a Bachelor of Arts in Biology from Yeshiva University.
In addition to his medical and business education, Silberstein is a Chartered Financial Analyst and a licensed physician in New York State.
His combination of clinical training and financial expertise is relevant to NovaBridge’s business model, which involves evaluating therapeutic assets, advancing clinical programs and determining appropriate financing and commercialization strategies.
“I am excited to join NovaBridge at such a compelling time in the Company’s development,” Silberstein said.
He cited the company’s portfolio of therapeutic assets and opportunities for clinical development, strategic partnerships and capital deployment as factors behind his decision to join the organization.
Silberstein said he intends to work with Gupta, the Board of Directors and the broader management team to advance NovaBridge’s strategic objectives and support its long-term development.
NovaBridge is focused on identifying and developing differentiated therapeutic assets while pursuing financing and partnership arrangements designed to support individual programs.
The company’s lead development program is givastomig, a Claudin 18.2 × 4-1BB bispecific antibody being investigated as a potential treatment for gastrointestinal malignancies.
Bispecific antibodies are engineered to engage two different molecular targets, providing a potential approach to treating diseases through coordinated biological mechanisms.
Givastomig is designed to target Claudin 18.2 and 4-1BB, with development focused on evaluating its potential in gastrointestinal cancers.
The program represents a central component of NovaBridge’s clinical development portfolio.
NovaBridge also owns a majority interest in Visara, an ophthalmology subsidiary developing a portfolio of therapeutic programs intended to address unmet medical needs involving diseases affecting the front and back of the eye.
Through Visara, the company is building an ophthalmology business alongside its oncology development activities.
The combination of oncology and ophthalmology programs creates distinct development and financing considerations, including clinical trial requirements, regulatory pathways and potential partnership opportunities.
NovaBridge’s strategy involves assessing these factors across its portfolio and selecting development, financing and partnering approaches appropriate to each asset.
For biotechnology companies advancing clinical-stage therapies, access to capital and disciplined financial management are important considerations because development programs can require substantial investment before potential commercialization.
Strategic partnerships and financing transactions can provide additional resources while allowing companies to allocate capital among competing development priorities.
Silberstein’s background in public-company finance, biotechnology operations and healthcare investing will support NovaBridge as it evaluates these opportunities.
The company has not announced specific financing transactions or changes to its development programs in connection with the appointment.
The leadership transition establishes new financial oversight as NovaBridge continues advancing givastomig and developing its ophthalmology portfolio through Visara.
With Silberstein assuming the Chief Financial Officer position in November, NovaBridge adds an executive experienced in capital markets and biotechnology strategy to support its clinical development priorities, financial planning and potential strategic transactions.